NCT00830557

Brief Summary

RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic disorders in the future. PURPOSE: This clinical trial is collecting medical information and tissue samples from patients with pancreatic cancer or other pancreatic disorders.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20,000

participants targeted

Target at P75+ for all trials

Timeline
16mo left

Started Oct 2000

Longer than P75 for all trials

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Oct 2000Aug 2027

Study Start

First participant enrolled

October 1, 2000

Completed
8.3 years until next milestone

First Submitted

Initial submission to the registry

January 27, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 28, 2009

Completed
18.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2027

Last Updated

March 9, 2026

Status Verified

March 1, 2026

Enrollment Period

26.9 years

First QC Date

January 27, 2009

Last Update Submit

March 5, 2026

Conditions

Pancreatic DiseaseAcute PancreatitisChronic PancreatitisHereditary PancreatitisPancreatic Neuroendocrine CarcinomaIslet Cell TumorPancreatic CancerPancreatic Adenocarcinoma

Keywords

recurrent pancreatic cancerstage I pancreatic cancerstage II pancreatic cancerstage III pancreatic cancerstage IV pancreatic cancerrecurrent islet cell carcinomapancreatic alpha cell carcinomapancreatic beta islet cell carcinomapancreatic delta cell carcinomapancreatic G-cell carcinoma

Outcome Measures

Primary Outcomes (3)

  • Collection of clinical data, health and family histories by survey

    baseline enrollment, 6 months, 12 months

  • Collection of blood and/or tissue, fecal and oral specimens

    baseline

  • Collection of information regarding food preparation and intake by survey

    baseline

Study Arms (1)

Observational

Patients undergo blood, saliva, and previously obtained leftover tissue sample collection on study. Patients also complete questionnaires and have their medical records reviewed on study.

Other: medical chart reviewOther: survey administrationOther: biospecimen collection

Interventions

medical chart reviewOTHER

baseline, 12 month and 36 months

Observational
survey administrationOTHER

baseline, 6 month, 12 month

Observational
biospecimen collectionOTHER

baseline

Observational

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with known or suspected pancreas disease including pancreas adenocarcinoma, islet cell cancer, pancreatic cysts, pancreatitis (hereditary, acute, or chronic) or the next of kin of deceased participants.

You may not qualify if:

  • Under the age of 18
  • Unable to provide informed consent
  • Prison inmates

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054, United States

RECRUITING

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States

RECRUITING

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

RECRUITING

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Two 10mL plasma tubes, two 10mL serum tubes and one 10mL heparin tube collected. DNA extracted from lymphocytes. Possible saliva collection for DNA extraction. Waste tissue from prior surgery may be collected. Stool samples may be collected.

MeSH Terms

Conditions

Adenoma, Islet CellPancreatic NeoplasmsPancreatic DiseasesPancreatitisPancreatitis, ChronicHereditary pancreatitisSomatostatinomaCarcinoma, Islet Cell

Condition Hierarchy (Ancestors)

AdenomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsDigestive System NeoplasmsNeoplasms by SiteEndocrine Gland NeoplasmsDigestive System DiseasesEndocrine System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsCarcinoma, NeuroendocrineNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalAdenocarcinomaCarcinoma

Study Officials

  • Shounak Majumder, MD

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Adriana Delgado, MA

CONTACT

800-914-7962pancreas@mayo.edu

Heather M Streich, CCRP

CONTACT

800-914-7962pancreas@mayo.edu

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 27, 2009

First Posted

January 28, 2009

Study Start

October 1, 2000

Primary Completion (Estimated)

August 30, 2027

Study Completion (Estimated)

August 30, 2027

Last Updated

March 9, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations

US(3)